News
OMER
3.080
+0.98%
0.030
Weekly Report: what happened at OMER last week (0415-0419)?
Weekly Report · 20h ago
Weekly Report: what happened at OMER last week (0408-0412)?
Weekly Report · 04/15 12:11
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Omeros (OMER) and Urogen Pharma (URGN)
TipRanks · 04/09 11:40
Weekly Report: what happened at OMER last week (0401-0405)?
Weekly Report · 04/08 12:17
Omeros Corporation’s $50M Buyback Plan: A Double-Edged Sword for Stock Stability
TipRanks · 04/03 06:01
Omeros Shares Down 6% on Swing to 4Q Loss
Omeros shares edged down 6% to $3 a reporting a swing to a loss in the fourth quarter. The stock is down 8.3% so far this year. The biopharmaceutical company posted a loss of $9.1 million in theFourth quarter.
Dow Jones · 04/02 15:07
CORRECTION: Omeros Q4 EPS $(0.63) Misses $(0.55) Estimate
Benzinga · 04/02 12:05
Omeros (OMER) Gets a Hold from Needham
TipRanks · 04/02 10:27
OMER Stock Earnings: Omeros Misses EPS for Q4 2023
Omeros reported earnings per share of -63 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was below the analyst estimate for EPS of -55 cents. Omeros also reported results for the third quarter of 2018.
Investorplace · 04/02 01:53
Omeros Corp reports results for the quarter ended in December - Earnings Summary
Omeros Corp reports results for the quarter ended in December. Reported revenue was zero; analysts expected zero. The company reported a quarterly loss of $9.07 million. Omeros Corporation shares had held steady so far this quarter and gained 5.5% this year.
Reuters · 04/01 21:01
Omeros Corp. Q4 Earnings Summary
NASDAQ · 04/01 20:40
Omeros GAAP EPS of -$0.63 misses by $0.07
Seeking Alpha · 04/01 20:05
Omeros Q4 2023 GAAP EPS $(0.15) Beats $(0.56) Estimate
Benzinga · 04/01 20:03
OMEROS CORP - NET LOSS FOR Q4 OF 2023 WAS $9.1 MLN, OR $0.15 PER SHARE
Reuters · 04/01 20:02
*Omeros 4Q Loss/Shr 15c >OMER
Dow Jones · 04/01 20:02
Press Release: Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results
Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results. The company will hold a conference call today at 4:30 p.m. ET. Omeros is a clinical-stage biopharmaceutical company. Company reports financial results for the fourth quarter and year ended December 31, 2023.
Dow Jones · 04/01 20:02
*Omeros 4Q Loss $9.07M >OMER
Dow Jones · 04/01 20:02
Omeros: Q4 Earnings Snapshot
Omeros Corporation reports a loss of $9.1 million in its fourth quarter. The Seattle-based company said it had a Loss of 15 cents per share in the quarter. For the year, the company reported a Losses of $117.8 million.
Barchart · 04/01 15:17
Weekly Report: what happened at OMER last week (0325-0329)?
Weekly Report · 04/01 12:14
Options Volatility and Implied Earnings Moves Today, April 01, 2024
TipRanks · 04/01 11:05
More
Webull provides a variety of real-time OMER stock news. You can receive the latest news about Omeros through multiple platforms. This information may help you make smarter investment decisions.
About OMER
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.